Níall Lally
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Níall Lally has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Paul Roiser
Institute of Cognitive Neuroscience, University College London
3 shared publications - Allison Carol Nugent
Magnetoencephalography Core Facility, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, United States
2 shared publications - Jörn Diedrichsen
Western Institute of Neuroscience, Western University, London, Ontario, Canada
2 shared publications - Mark J. Niciu
University of Iowa Health Care
2 shared publications A C Nugent
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
1 shared publicationAnat Chemerinski
Human Genetics Branch, Division of Intramural Research Programs, National Institute of Mental Health (NIMH), National Institutes of Health (NIH), Bethesda, Maryland
1 shared publication
Latest Publications
- 11 November 2026
- Published by Wiley in Journal of Intellectual Disability Research
Anticholinergic Burden in People With Intellectual Disability
Background: Individuals with intellectual disability (ID) experience high rates of multimorbidity and psychotropic prescribing, placing them at greater risk of anticholinergic burden (ACB), which has been associated with adverse cognitive and physical health outcomes. However, data on ACB among people with an ID attending specialist mental health services remain limited. Methods: A retrospective chart review was conducted for all adults with an ID ( N = 159) attending a specialist mental health service. Demographic, clinical and prescribing data were extracted from clinical records. ACB was determined using the online ACB Calculator. Rates of psychiatric and physical health comorbidity and prescribing were examined. Results: Elevated ACB was common, with 65% of service users recording clinically significant scores. ACB was higher in females and those in residential services and positively correlated with age and total medication burden but did not differ according to ID level. Polypharmacy was present in 57% of service users, and antipsychotics were the most frequently prescribed psychotropic medication (82%). Individuals with Down syndrome demonstrated lower ACB scores than those without. In multivariate analyses, the number of prescribed medications and antipsychotics independently predicted clinically significant ACB. Conclusions: Adults with an ID attending specialist mental health services experience substantial exposure to anticholinergic medications within the context of multimorbidity and polypharmacy. Elevated ACB appears to be driven by overall medication burden and psychotropic prescribing, particularly antipsychotic use. Routine assessment of ACB alongside individual‐reported experiences and clinician‐rated outcomes should form part of regular medication review processes to identify potentially modifiable prescribing risks and support safer pharmacological management. Future research should examine whether interventions that reduce ACB improve subjective, clinician‐rated and broader health outcomes in ID.
- 11 November 2026
- Published by Wiley in Journal of Intellectual Disability Research
Anticholinergic Burden in People With Intellectual Disability
Background: Individuals with intellectual disability (ID) experience high rates of multimorbidity and psychotropic prescribing, placing them at greater risk of anticholinergic burden (ACB), which has been associated with adverse cognitive and physical health outcomes. However, data on ACB among people with an ID attending specialist mental health services remain limited. Methods: A retrospective chart review was conducted for all adults with an ID ( N = 159) attending a specialist mental health service. Demographic, clinical and prescribing data were extracted from clinical records. ACB was determined using the online ACB Calculator. Rates of psychiatric and physical health comorbidity and prescribing were examined. Results: Elevated ACB was common, with 65% of service users recording clinically significant scores. ACB was higher in females and those in residential services and positively correlated with age and total medication burden but did not differ according to ID level. Polypharmacy was present in 57% of service users, and antipsychotics were the most frequently prescribed psychotropic medication (82%). Individuals with Down syndrome demonstrated lower ACB scores than those without. In multivariate analyses, the number of prescribed medications and antipsychotics independently predicted clinically significant ACB. Conclusions: Adults with an ID attending specialist mental health services experience substantial exposure to anticholinergic medications within the context of multimorbidity and polypharmacy. Elevated ACB appears to be driven by overall medication burden and psychotropic prescribing, particularly antipsychotic use. Routine assessment of ACB alongside individual‐reported experiences and clinician‐rated outcomes should form part of regular medication review processes to identify potentially modifiable prescribing risks and support safer pharmacological management. Future research should examine whether interventions that reduce ACB improve subjective, clinician‐rated and broader health outcomes in ID.
- Open Access
- 23 March 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (5) , 687-702
Trip killers: Addressing a critical knowledge gap in psychedelic research
Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a “bad trip.” Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require presentation to accident and emergency departments and psychiatric hospital admission. Managing such cases requires careful consideration, with priority given to non-pharmacological strategies. When these measures prove insufficient, an alternative approach may be necessary, one that can effectively attenuate or terminate the psychedelic state and restore psychological stability. Despite clinical relevance, there is no systematic evaluation of pharmacological interventions to terminate such experiences. This review identifies and critically appraises candidate medications with potential utility as abortive agents, including serotonin antagonists, drugs for psychosis, and select drugs for anxiety and depression. We review these agents, their mechanisms of action, pharmacokinetics, safety profiles, and applicability in acute care settings. Binding strength at the molecular level, potency to functionally block receptor-mediated effects, and lack of side effects are key considerations. We conclude by proposing a provisional framework for the pharmacologic management of adverse psychedelic experiences and highlight key priorities for future research.
- 23 March 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (5) , 687-702
Open AccessTrip killers: Addressing a critical knowledge gap in psychedelic research
Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a “bad trip.” Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require presentation to accident and emergency departments and psychiatric hospital admission. Managing such cases requires careful consideration, with priority given to non-pharmacological strategies. When these measures prove insufficient, an alternative approach may be necessary, one that can effectively attenuate or terminate the psychedelic state and restore psychological stability. Despite clinical relevance, there is no systematic evaluation of pharmacological interventions to terminate such experiences. This review identifies and critically appraises candidate medications with potential utility as abortive agents, including serotonin antagonists, drugs for psychosis, and select drugs for anxiety and depression. We review these agents, their mechanisms of action, pharmacokinetics, safety profiles, and applicability in acute care settings. Binding strength at the molecular level, potency to functionally block receptor-mediated effects, and lack of side effects are key considerations. We conclude by proposing a provisional framework for the pharmacologic management of adverse psychedelic experiences and highlight key priorities for future research.
- 1 August 2015
- Published by Elsevier in Neuroscience Research
- Vol. 97, 45-51
Dispositional mindfulness and semantic integration of emotional words: Evidence from event-related brain potentials
- 1 August 2015
- Published by Elsevier in Neuroscience Research
- Vol. 97, 45-51
Dispositional mindfulness and semantic integration of emotional words: Evidence from event-related brain potentials
- 7 June 2015
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 43 (1) , 88-98
Reliability of 7T1H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation
Purpose To ascertain the mechanisms of neuropsychiatric illnesses and their treatment, accurate and reliable imaging techniques are required; proton magnetic resonance spectroscopy (1H‐MRS) can noninvasively measure glutamatergic function. Evidence suggests that aberrant glutamatergic signaling plays a role in numerous psychopathologies. Until recently, overlapping glutamatergic signals (glutamate, glutamine, and glutathione) could not easily be separated. However, the advent of novel pulse sequences and higher field magnetic resonance imaging (MRI) allows more precise resolution of overlapping glutamatergic signals, although the question of signal reliability remains undetermined. Materials and Methods At 7T MR, we acquired 1H‐MRS data from the medial pregenual anterior cingulate cortex of healthy volunteers (n = 26) twice on two separate days. An adapted echo time optimized point‐resolved spectroscopy sequence, modified with the addition of a J‐suppression pulse to attenuate N‐acetyl‐aspartate multiplet signals at 2.49 ppm, was used to excite and acquire the spectra. In‐house software was used to model glutamate, glutamine, and glutathione, among other metabolites, referenced to creatine. Intraclass correlation coefficients (ICCs) were computed for within‐ and between‐session measurements. Results Within‐session measurements of glutamate, glutamine, and glutathione were on average reliable (ICCs ≥0.7). As anticipated, ICCs for between‐session values of glutamate, glutamine, and glutathione were slightly lower but nevertheless reliable (ICC >0.62). A negative correlation was observed between glutathione concentration and age (r(24) = –0.37; P < 0.05), and a gender effect was noted on glutamine and glutathione. Conclusion The adapted sequence provides good reliability to measure glutamate, glutamine, and glutathione signals. J. MAGN. RESON. IMAGING 2016;43:88–98.
- 7 June 2015
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 43 (1) , 88-98
Reliability of 7T1H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation
Purpose To ascertain the mechanisms of neuropsychiatric illnesses and their treatment, accurate and reliable imaging techniques are required; proton magnetic resonance spectroscopy (1H‐MRS) can noninvasively measure glutamatergic function. Evidence suggests that aberrant glutamatergic signaling plays a role in numerous psychopathologies. Until recently, overlapping glutamatergic signals (glutamate, glutamine, and glutathione) could not easily be separated. However, the advent of novel pulse sequences and higher field magnetic resonance imaging (MRI) allows more precise resolution of overlapping glutamatergic signals, although the question of signal reliability remains undetermined. Materials and Methods At 7T MR, we acquired 1H‐MRS data from the medial pregenual anterior cingulate cortex of healthy volunteers (n = 26) twice on two separate days. An adapted echo time optimized point‐resolved spectroscopy sequence, modified with the addition of a J‐suppression pulse to attenuate N‐acetyl‐aspartate multiplet signals at 2.49 ppm, was used to excite and acquire the spectra. In‐house software was used to model glutamate, glutamine, and glutathione, among other metabolites, referenced to creatine. Intraclass correlation coefficients (ICCs) were computed for within‐ and between‐session measurements. Results Within‐session measurements of glutamate, glutamine, and glutathione were on average reliable (ICCs ≥0.7). As anticipated, ICCs for between‐session values of glutamate, glutamine, and glutathione were slightly lower but nevertheless reliable (ICC >0.62). A negative correlation was observed between glutathione concentration and age (r(24) = –0.37; P < 0.05), and a gender effect was noted on glutamine and glutathione. Conclusion The adapted sequence provides good reliability to measure glutamate, glutamine, and glutathione signals. J. MAGN. RESON. IMAGING 2016;43:88–98.
- Open Access
- 17 February 2015
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 29 (5) , 596-607
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine
Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists. In this exploratory re-analysis, we assessed whether administration of rapid-acting antidepressant ketamine was associated specifically with reduced anhedonia in medication-free treatment-refractory patients with major depressive disorder in an open-label investigation. Additionally, participants received either oral riluzole or placebo daily beginning 4 hours post-infusion. A subgroup of patients underwent fluorodeoxyglucose positron emission tomography scans at baseline (1–3 days pre-infusion) and 2 hours post-ketamine infusion. Anhedonia rapidly decreased following a single ketamine infusion; this was sustained for up to three days, but was not altered by riluzole. Reduced anhedonia correlated with increased glucose metabolism in the hippocampus and dorsal anterior cingulate cortex (dACC) and decreased metabolism in the inferior frontal gyrus and orbitofrontal cortex (OFC). The tentative relationship between change in anhedonia and glucose metabolism remained significant in dACC and OFC, and at trend level in the hippocampus, a result not anticipated, when controlling for change in total depression score. Results, however, remain tenuous due to the lack of a placebo control for ketamine. In addition to alleviating overall depressive symptoms, ketamine could possess anti-anhedonic potential in major depressive disorder, which speculatively, may be mediated by alterations in metabolic activity in the hippocampus, dACC and OFC.
- 17 February 2015
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 29 (5) , 596-607
Open AccessNeural correlates of change in major depressive disorder anhedonia following open-label ketamine
Anhedonia is a cardinal symptom of major depression and is often refractory to standard treatment, yet no approved medication for this specific symptom exists. In this exploratory re-analysis, we assessed whether administration of rapid-acting antidepressant ketamine was associated specifically with reduced anhedonia in medication-free treatment-refractory patients with major depressive disorder in an open-label investigation. Additionally, participants received either oral riluzole or placebo daily beginning 4 hours post-infusion. A subgroup of patients underwent fluorodeoxyglucose positron emission tomography scans at baseline (1–3 days pre-infusion) and 2 hours post-ketamine infusion. Anhedonia rapidly decreased following a single ketamine infusion; this was sustained for up to three days, but was not altered by riluzole. Reduced anhedonia correlated with increased glucose metabolism in the hippocampus and dorsal anterior cingulate cortex (dACC) and decreased metabolism in the inferior frontal gyrus and orbitofrontal cortex (OFC). The tentative relationship between change in anhedonia and glucose metabolism remained significant in dACC and OFC, and at trend level in the hippocampus, a result not anticipated, when controlling for change in total depression score. Results, however, remain tenuous due to the lack of a placebo control for ketamine. In addition to alleviating overall depressive symptoms, ketamine could possess anti-anhedonic potential in major depressive disorder, which speculatively, may be mediated by alterations in metabolic activity in the hippocampus, dACC and OFC.
- Open Access
- 14 October 2014
- Published by Springer Nature in Translational Psychiatry
- Vol. 4 (10) , e469
Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression
Anhedonia—which is defined as diminished pleasure from, or interest in, previously rewarding activities—is one of two cardinal symptoms of a major depressive episode. However, evidence suggests that standard treatments for depression do little to alleviate the symptoms of anhedonia and may cause reward blunting. Indeed, no therapeutics are currently approved for the treatment of anhedonia. Notably, over half of patients diagnosed with bipolar disorder experience significant levels of anhedonia during a depressive episode. Recent research into novel and rapid-acting therapeutics for depression, particularly the noncompetitive N-Methyl-D-aspartate receptor antagonist ketamine, has highlighted the role of the glutamatergic system in the treatment of depression; however, it is unknown whether ketamine specifically improves anhedonic symptoms. The present study used a randomized, placebo-controlled, double-blind crossover design to examine whether a single ketamine infusion could reduce anhedonia levels in 36 patients with treatment-resistant bipolar depression. The study also used positron emission tomography imaging in a subset of patients to explore the neurobiological mechanisms underpinning ketamine’s anti-anhedonic effects. We found that ketamine rapidly reduced the levels of anhedonia. Furthermore, this reduction occurred independently from reductions in general depressive symptoms. Anti-anhedonic effects were specifically related to increased glucose metabolism in the dorsal anterior cingulate cortex and putamen. Our study emphasizes the importance of the glutamatergic system in treatment-refractory bipolar depression, particularly in the treatment of symptoms such as anhedonia.
- 14 October 2014
- Published by Springer Nature in Translational Psychiatry
- Vol. 4 (10) , e469
Open AccessAnti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression
Anhedonia—which is defined as diminished pleasure from, or interest in, previously rewarding activities—is one of two cardinal symptoms of a major depressive episode. However, evidence suggests that standard treatments for depression do little to alleviate the symptoms of anhedonia and may cause reward blunting. Indeed, no therapeutics are currently approved for the treatment of anhedonia. Notably, over half of patients diagnosed with bipolar disorder experience significant levels of anhedonia during a depressive episode. Recent research into novel and rapid-acting therapeutics for depression, particularly the noncompetitive N-Methyl-D-aspartate receptor antagonist ketamine, has highlighted the role of the glutamatergic system in the treatment of depression; however, it is unknown whether ketamine specifically improves anhedonic symptoms. The present study used a randomized, placebo-controlled, double-blind crossover design to examine whether a single ketamine infusion could reduce anhedonia levels in 36 patients with treatment-resistant bipolar depression. The study also used positron emission tomography imaging in a subset of patients to explore the neurobiological mechanisms underpinning ketamine’s anti-anhedonic effects. We found that ketamine rapidly reduced the levels of anhedonia. Furthermore, this reduction occurred independently from reductions in general depressive symptoms. Anti-anhedonic effects were specifically related to increased glucose metabolism in the dorsal anterior cingulate cortex and putamen. Our study emphasizes the importance of the glutamatergic system in treatment-refractory bipolar depression, particularly in the treatment of symptoms such as anhedonia.
- Open Access
- 1 January 2014
- Published by Elsevier in NeuroImage
- Vol. 85, 823-833
Glutamatergic correlates of gamma-band oscillatory activity during cognition: A concurrent ER-MRS and EEG study
- 1 January 2014
- Published by Elsevier in NeuroImage
- Vol. 85, 823-833
Open AccessGlutamatergic correlates of gamma-band oscillatory activity during cognition: A concurrent ER-MRS and EEG study
- 1 December 2012
- Published by Elsevier in Biological Psychiatry
- Vol. 72 (11) , e27-e28
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients
- 1 December 2012
- Published by Elsevier in Biological Psychiatry
- Vol. 72 (11) , e27-e28
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients
- Open Access
- 1 January 2012
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 107 (1) , 134-147
Cerebellar regions involved in adaptation to force field and visuomotor perturbation
The induction of long-term potentiation (LTP) and long-term depression (LTD) of excitatory postsynaptic currents was investigated in proximal synapses of layer 2/3 pyramidal cells of the rat medial prefrontal cortex. The spike timing-dependent plasticity (STDP) induction protocol of negative timing, with postsynaptic leading presynaptic stimulation of action potentials (APs), induced LTD as expected from the classical STDP rule. However, the positive STDP protocol of presynaptic leading postsynaptic stimulation of APs predominantly induced a presynaptically expressed LTD rather than the expected postsynaptically expressed LTP. Thus the induction of plasticity in layer 2/3 pyramidal cells does not obey the classical STDP rule for positive timing. This unusual STDP switched to a classical timing rule if the slow Ca2+-dependent, K+-mediated afterhyperpolarization (sAHP) was inhibited by the selective blocker N-trityl-3-pyridinemethanamine (UCL2077), by the β-adrenergic receptor agonist isoproterenol, or by the cholinergic agonist carbachol. Thus we demonstrate that neuromodulators can affect synaptic plasticity by inhibition of the sAHP. These findings shed light on a fundamental question in the field of memory research regarding how environmental and behavioral stimuli influence LTP, thereby contributing to the modulation of memory.
- 1 January 2012
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 107 (1) , 134-147
Open AccessCerebellar regions involved in adaptation to force field and visuomotor perturbation
The induction of long-term potentiation (LTP) and long-term depression (LTD) of excitatory postsynaptic currents was investigated in proximal synapses of layer 2/3 pyramidal cells of the rat medial prefrontal cortex. The spike timing-dependent plasticity (STDP) induction protocol of negative timing, with postsynaptic leading presynaptic stimulation of action potentials (APs), induced LTD as expected from the classical STDP rule. However, the positive STDP protocol of presynaptic leading postsynaptic stimulation of APs predominantly induced a presynaptically expressed LTD rather than the expected postsynaptically expressed LTP. Thus the induction of plasticity in layer 2/3 pyramidal cells does not obey the classical STDP rule for positive timing. This unusual STDP switched to a classical timing rule if the slow Ca2+-dependent, K+-mediated afterhyperpolarization (sAHP) was inhibited by the selective blocker N-trityl-3-pyridinemethanamine (UCL2077), by the β-adrenergic receptor agonist isoproterenol, or by the cholinergic agonist carbachol. Thus we demonstrate that neuromodulators can affect synaptic plasticity by inhibition of the sAHP. These findings shed light on a fundamental question in the field of memory research regarding how environmental and behavioral stimuli influence LTP, thereby contributing to the modulation of memory.
- Open Access
- 14 April 2010
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 30 (15) , 5159-5166
Use-Dependent and Error-Based Learning of Motor Behaviors
Human motor behavior is constantly adapted through the process of error-based learning. When the motor system encounters an error, its estimate about the body and environment will change, and the next movement will be immediately modified to counteract the underlying perturbation. Here, we show that a second mechanism, use-dependent learning, simultaneously changes movements to become more similar to the last movement. In three experiments, participants made reaching movements toward a horizontally elongated target, such that errors in the initial movement direction did not have to be corrected. Along this task-redundant dimension, we were able to induce use-dependent learning by passively guiding movements in a direction angled by 8° from the previous direction. In a second study, we show that error-based and use-dependent learning can change motor behavior simultaneously in opposing directions by physically constraining the direction of active movements. After removal of the constraint, participants briefly exhibit an error-based aftereffect against the direction of the constraint, followed by a longer-lasting use-dependent aftereffect in the direction of the constraint. In the third experiment, we show that these two learning mechanisms together determine the solution the motor system adopts when learning a motor task.
- 14 April 2010
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 30 (15) , 5159-5166
Open AccessUse-Dependent and Error-Based Learning of Motor Behaviors
Human motor behavior is constantly adapted through the process of error-based learning. When the motor system encounters an error, its estimate about the body and environment will change, and the next movement will be immediately modified to counteract the underlying perturbation. Here, we show that a second mechanism, use-dependent learning, simultaneously changes movements to become more similar to the last movement. In three experiments, participants made reaching movements toward a horizontally elongated target, such that errors in the initial movement direction did not have to be corrected. Along this task-redundant dimension, we were able to induce use-dependent learning by passively guiding movements in a direction angled by 8° from the previous direction. In a second study, we show that error-based and use-dependent learning can change motor behavior simultaneously in opposing directions by physically constraining the direction of active movements. After removal of the constraint, participants briefly exhibit an error-based aftereffect against the direction of the constraint, followed by a longer-lasting use-dependent aftereffect in the direction of the constraint. In the third experiment, we show that these two learning mechanisms together determine the solution the motor system adopts when learning a motor task.